Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Sun Yat-sen University

Status and phase

Enrolling

Phase 2

Conditions

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Treatments

Drug: Adebrelimab, Apatinib, Gemcitabine, cisplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT06280508

SYSKY-2024-082-01

Details and patient eligibility

About

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

confirmed intrahepatic cholangiocarcinoma
with Resectable tumor lesion
no contraindications to surgery
with high risk of tumour recurrence
No prior systemic therapy for intrahepatic cholangiocarcinoma.
ECOG Performance Status of 0 or 1
Child-Pugh Class: Grade A

Exclusion criteria

History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
Known genetic or acquired hemorrhage or thrombotic tendency
Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
Cardiac clinical symptom or disease that is not well controlled
Hypertension that can not be well controlled through antihypertensive drugs